Search results for "IBA"

showing 10 items of 1355 documents

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Long-Term Results after Interval Therapy with Intratympanic Gentamicin for Meni??re???s Disease

2004

Objectives The new single-shot and interval treatment for Meniere's disease with gentamicin was designed to avoid cochlear damage during treatment with gentamicin. Methods To date, 90 patients were treated with the single-shot or interval gentamicin therapy. Fifty-seven cases of Meniere's disease were followed up prospectively between 2 and 4 years. During one treatment series, a maximum of three intratympanic gentamicin injections within 15 days were applied, each consisting of 0.3 mL (12 mg) of gentamicin (days 1, 8, and 15). Thirty of these 57 patients (53%) needed only one injection to be controlled (single-shot treatment). Results Vertigo attacks were completely controlled in 95% and p…

Malemedicine.medical_specialtyTime FactorsTympanic MembraneHearing lossDrug Administration ScheduleOtotoxicityVertigomedicineHumansProspective StudiesMeniere DiseaseAntibacterial agentbiologybusiness.industryAminoglycosideMiddle Agedmedicine.diseasebiology.organism_classificationAnti-Bacterial AgentsSurgeryTreatment OutcomeOtorhinolaryngologyFemaleGentamicinGentamicinsmedicine.symptombusinessTinnitusFollow-Up StudiesMeniere's diseasemedicine.drugThe Laryngoscope
researchProduct

Endogenous oxytocin is essential for the buffering effects of pair housing against the increase in cocaine reward induced by social stress.

2019

Social factors have a dual influence on addictive disorders. While social defeat stress in rodents increases the response to drug reward, positive social conditions, such as pair housing, increase stress resilience. The objective of the present study was to confirm whether oxytocin (OT) mediates this social buffering. To this end, male mice were housed in pairs and administered the OT receptor antagonist atosiban prior to each stress episode or for ten days after the stress protocol. The response to cocaine was assessed using a conditioned place preference paradigm. Our results confirmed that OT activity mediates the protective effect of pair housing and highlights its therapeutic potential.

Malemedicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectExperimental and Cognitive PsychologyEndogenyOxytocinSocial defeat03 medical and health sciencesBehavioral NeuroscienceMice0302 clinical medicineCocaineRewardInternal medicinemedicineAnimals0501 psychology and cognitive sciences050102 behavioral science & comparative psychologySocial Behaviormedia_commonSocial stressbusiness.industryAddiction05 social sciencesAtosibanReceptor antagonistConditioned place preferenceEndocrinologyOxytocinHousingbusiness030217 neurology & neurosurgeryStress Psychologicalmedicine.drugPhysiologybehavior
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct

ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or Peg-IFN plus ribavirin

2003

The aim of the study was to characterize the interferon sensitivity determining region (ISDR) mutation pattern and its changes at 4 weeks of treatment in a population of patients infected with hepatitis C virus (HCV) genotype 1b receiving standard or PEG-IFN plus ribavirin (RBV), to find possible early correlates of therapy outcome.Forty-five patients with chronic hepatitis due to HCV 1b were treated by PEG-IFN-α2b (n=23) or IFN-α2b (n=22) plus RBV 1000–1200 mg/day. They were classified 24 weeks after stopping therapy as sustained responders (SR), relapsers (REL) or non-responders (NR). Sixteen patients were SR, 12 REL and 17 NR. ISDR mutations were evaluated by direct sequencing at baselin…

Malemedicine.medical_treatmentHepacivirusHepacivirusViral Nonstructural Proteinsmedicine.disease_causePolyethylene GlycolPolyethylene GlycolsCohort Studieschemistry.chemical_compoundInterferonMedicinePharmacology (medical)education.field_of_studybiologyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleHumanmedicine.drugGenotypeHepatitis C virusMolecular Sequence DataPopulationInterferon alpha-2Antiviral AgentsVirusFlaviviridaeRibavirinHumansAmino Acid SequenceeducationAntiviral AgentPharmacologyChemotherapyHepacivirubusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiology.organism_classificationVirologychemistryMutationCohort StudiebusinessSequence Alignment
researchProduct

Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats

2020

Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…

MalesuolistomikrobistoPROGRESSIONBIFIDOBACTERIASTEATOHEPATITISNon-alcoholic Fatty Liver DiseaseCecumDiet Fat-RestrictedaineenvaihduntaFatty Acidsrasvamaksafood and beveragesmitochondriaLiverprebioticBody CompositionBIOPSIESFemaleOxidation-Reductionlcsh:Nutrition. Foods and food supplymitokondriotGlucuronateslcsh:TX341-641Diet High-Fatdigestive systemArticleDYSBIOSISprebiootitINFLAMMATIONLIVER-DISEASEINTESTINAL MICROBIOTAoligosaccharidesoligosakkariditAnimalsRats WistarTriglyceridesfatty livergut microbiotaFaecalibacterium prausnitziinutritional and metabolic diseasesLipid MetabolismGastrointestinal MicrobiomeRatsFAECALIBACTERIUM-PRAUSNITZIIGlucosePrebiotics416 Food Scienceaineenvaihduntatuotteet3111 BiomedicineEnergy IntakeEnergy MetabolismmetabolismNutrients
researchProduct

Urinary tract infections in children: EAU/ESPU guidelines.

2015

Context: In 30% of children with urinary tract anomalies, urinary tract infection (UTI) can be the first sign. Failure to identify patients at risk can result in damage to the upper urinary tract.Objective: To provide recommendations for the diagnosis, treatment, and imaging of children presenting with UTI.Evidence acquisition: The recommendations were developed after a review of the literature and a search of PubMed and Embase. A consensus decision was adopted when evidence was low.Evidence synthesis: UTIs are classified according to site, episode, symptoms, and complicating factors. For acute treatment, site and severity are the most important. Urine sampling by suprapubic aspiration or c…

Maleurologic and male genital diseasesPediatricsSeverity of Illness IndexESPUVOIDING CYSTOURETHROGRAPHYFollow-up imagingSuprapubic aspirationRisk FactorsDiagnosisguidelinesAntibiotic prophylaxisChildChildrenObstructive uropathyUpper urinary tractUrinary tract infectionDiagnostic Techniques Urologicalfemale genital diseases and pregnancy complicationsAnti-Bacterial AgentsTreatment OutcomeEAUAntibacterial treatmentUrinary Tract InfectionsFemalePRIMARY VESICOURETERAL REFLUXmedicine.symptomYOUNG-CHILDRENmedicine.medical_specialtyUrologyRenal scarUrologyBacteriuriaCONTROLLED-TRIALSUPRAPUBIC ASPIRATIONVesicoureteral reflux1ST FEBRILE UTIANTIBIOTIC-PROPHYLAXISPredictive Value of TestsUrine samplingInternal medicineUltrasoundmedicineHumansTRANSABDOMINAL ULTRASOUNDACUTE PYELONEPHRITISbusiness.industryInfant NewbornInfantmedicine.diseasePyuriaTreatmentLeukocyte esteraseFOLLOW-UPbusinessEuropean urology
researchProduct

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…

2013

International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…

Maleviruses[SDV]Life Sciences [q-bio]Hepacivirusmedicine.disease_causeGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawErythropoiesisIncidenceGastroenterologyDisease Managementvirus diseasesAnemiaMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.drugmedicine.medical_specialtyGenotypeProlineSide effectAnemiaHepatitis C virusInterferon alpha-2Antiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinmedicineHumansErythropoietinDAADose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiochemical phenomena metabolism and nutritionmedicine.diseasedigestive system diseasesSide EffectLogistic ModelschemistryErythropoietinImmunologyHemoglobinbusinessEPO
researchProduct

Starpdisciplinārie pētījumi medicīnas koledžās : tēžu krājums

2021

Latvijas Universitātes 79. starptautiskās zinātniskās konferences “Starpdisciplinārie pētījumi medicīnas koledžās” tēzes raksturo medicīnas koledžās veikto pētījumu daudzpusību, pētniecības kvalitāti un arī lietišķumu, kas šogad izceļas ar raksturvārdiem “drošība” un “atbildība”. Konferencē prezentēto un diskutēto jautājumu loks ievērojami pārsniedz veselības aprūpē apskatīto jautājumu loku un veicinās studentus, pētniekus un sociālos partnerus aktīvāk sadarboties ne tikai studiju kvalitātes uzlabošanā, bet arī pētniecībā.

Malnutrīcijapacientu apkope:MEDICINE [Research Subject Categories]urīna nesaturēšanaVecmāšu darbība - vēstureDarba vides risks - sociālā aprūpeErgonomika masu praksēmasāžaKlausīšanās prasme (rehabitaloģija)Marfāna sindroms - aprūpes problēmasTiesu medicīnaKlasiskā kāju masāžaStudiju process- medicīnas koledžaDezinfekcijas līdzekļu efektivitāterehabilitācijaHallux valgusvides riskiAutonomija māsu praksēādas un nagu izmaiņasLipidogrammas rādītājiEelpceļu nodrošināšanaMedikamentozā aprūpe pēcoperācijas periodāHospitālās infekcijasOsteoartrīta pacienta dzīves kvalitātes pašnovērtējumsAntibakteriālo līdzekļu ietošanavīrusu izplatībaMotivācija darbam Neatliekamās medicīniskās palīdzības dienestāRoku mikrofloraRecepšu zāļu izsniegšanaKognitīvie traucējumiAtbalsta un izglītošanas programma nedzirdīgām grūtniecēm
researchProduct